EATCOVID could be a hit, MSB data as a proxy

First and foremost, anything to come out of EATCOVID is a complete bonus for this company. I believe $0 of the current market cap has anything from the Covid trial built into it.

MSB released some data on their Covid trial, and a slide on their presentation showed a clear differential between the number of T Cells for patients who have an "average" Covid case and a "severe" Covid case. For average cases, it shows that patients T Cells are at a decent level. But when you go over to the picture for severe cases, the patients T Cell levels are completely obliterated.

I'm assuming 95% of people here know that Efti increased and activates a patients T Cell function, which could give to the possibility of when given Efti, severe cases of Covid could be minimised to a great extent.

Keen on an update from the company after seeing this development.